How are you using liquid biopsy in the routine management of your patients with metastatic NSCLC?

The dramatic improvement in the prognosis of metastatic NSCLC patients harboring targetable oncogenic genetic alterations with highly effective therapy has underscored the need for tumor molecular profiling. There have been numerous studies in the past decade assessing the performance of ctDNA (here...

Circulating tumor DNA testing has quickly become an important part of my algorithms. At initial diagnosis, if the diagnostic specimen is cytologic, or a bone specimen (which often give indeterminate or false negative mutation results), or has been exhausted, ctDNA is a reasonable approach which can ...